Sun Pharma on Tuesday reported a better-than-expected 5.2% rise in third-quarter profit on Tuesday. According to the company, this growth was driven by higher sales of its specialty drugs.
The company‘s revenue from operations came in at ₹11,241 crore for the period under review. This is an increase of 14% from ₹9,863 crore clocked in the last year period.
The company has reported an EBITDA at ₹3,003.7 crore, with margins at 26.7%.
The company’s board has also declared an interim dividend of ₹7.50 for the financial year ending on 31 March, 2023.
Earlier, Sun Pharma had paid interim dividend of ₹7 per share for the previous financial year 2021-22.
